Severe diarrhea in renal transplant patients: Results of the DIDACT study

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1466-1472

  Maes, B ^a   Hadaya, K ^b   De Moor, B ^c   Cambier, P ^d   Peeters, P ^e   De Meester, J ^f   Donck, J ^g   Sennesael, J ^h   Squifflet, J P ⁱ  

^a Heilig Hart Ziekenhuis   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c VIRGA JESSE HOSPITAL   (Belgium)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f OLV HOSPITAL   (Belgium)

^g Algemeen Ziekenhuis Sint Lucas Gent   (Belgium)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Adverse effects; Immunosuppression; Infection; Kidney transplantation; Renal transplant; Severe diarrhea

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RAPAMYCIN; STEROID; TACROLIMUS; TETRACYCLINE DERIVATIVE; TICLOPIDINE;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARASITOSIS; PRIORITY JOURNAL; PROTOZOAL INFECTION; VIRUS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; BELGIUM; DIARRHEA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745810228     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01320.x     Document Type: Article

References (23)

1. Pescovitz MD, Navarro MT. Immunosuppressive therapy and post-transplantation diarrhea. Clin Transplant 2001; 15 (Suppl 4): 23-28.
2. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13: 277-287.
3. Shankar VK, Zilvetti M, Handa A, Bowler IC, Gray DW. Chronic diarrhea and weight loss due to vibrio parahaemolyticus infection in a renal transplant recipient. Transplantation 2004; 78: 487.
4. Altiparmak MR, Trablus S, Pamuk ON et al. Diarrhoea following renal transplantation. Clin Transplant 2002; 16: 212-216.
5. Maes BD, Lemahieu W, Kuypers D et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002; 2: 989-992.
6. Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc 2004; 36: 2096-2097.
7. Sato K, Amada N, Sato T et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant 2004; 18: 585-590.
8. Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: Mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993; 68: 691-702.
9. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
10. Rubin RH. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant 2001; 15(Suppl 4): 11-22.
11. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-205.
12. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-2386.
13. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
14. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The tricontinental mycophenolate mofetil renal transplantation study group. Transplantation 1996; 61: 1029-1037.
15. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
16. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
17. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
18. The European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European mycophenolate mofetil cooperative study group. Lancet 1995; 345: 1321-1325.
19. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
20. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383-1391.
21. Granger DK, ERL B 301 Renal Transplant Study Group; ERL B 302 Renal Transplant Study Group. Enteric-coated mycophenolate sodium: Results of two pivotal global multicenter trials. Transplant Proc 2001; 33: 3241-3244.
22. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237-243.
23. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236.